Biocon Biologics in March entered into a definitive agreement to acquire Viatris' biosimilars assets for $3.34 billion. It will pay Viatris $2 billion in cash at the closing of the deal, and another $335 million in 2024. Out of $2 billion, $800 million will come through equity infusion from existing investors including parent Biocon and others such as Serum Institute of India, Abu Dhabi-based ADQ, True North, Tata Capital Growth Fund and Goldman Sachs.from Industry-Economic Times
Read The Rest:economictimes...
